Crinetics Pharmaceuticals, Inc.: DRIEHAUS CAPITAL MANAGEMENT LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Driehaus Capital Management LLC amended its Schedule 13G filing on Crinetics Pharmaceuticals, Inc., updating its beneficial ownership stake with the SEC under accession number 0000938206-26-000050. The filing was disclosed via SEC EDGAR. The amendment signals a change in the institutional investor's position in the clinical-stage biopharmaceutical company. Investors will watch for further 13G or 13D filings to gauge whether Driehaus is accumulating or trimming its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Driehaus Capital Management LLC, Crinetics Pharmaceuticals, Inc.